Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer

Cellular Oncology

Volumn 31, Issue 1, 2009, Pages 11-17

  Calistri, Daniele ^a   Rengucci, Claudia ^a   Molinari, Chiara ^a   Ricci, Enrico ^b   Cavargini, Elena ^b   Scarpi, Emanuela ^a   Milandri, Gian Luigi ^c   Fabbri, Carla ^d   Ravaioli, Alberto ^d   Russo, Antonio ^e   Amadori, Dino ^a   Silvestrini, Rosella ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c BUFALINI HOSPITAL   (Italy)

^d Infermi Hospital   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

Colorectal cancer; Diagnosis; Fluorescence long DNA; Stool

Indexed keywords

DNA FRAGMENT; MOLECULAR MARKER;

AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SCREENING; CASE CONTROL STUDY; CLINICAL PRACTICE; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DNA DETERMINATION; EARLY DIAGNOSIS; FECES ANALYSIS; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCREENING TEST; VALIDATION STUDY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA; DNA PRIMERS; EARLY DETECTION OF CANCER; FECES; FEMALE; FLUORESCENT DYES; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149380020     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/847491     Document Type: Article

References (28)

1. D.A. Ahlquist, J.E. Skoletsky, K.A. Boynton, J.J. Harrington, D.W. Mahoney, W.E. Pierceall, S.N. Thibodeau and A.P. Shuber, Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel, Gastroenterology 119 (2000), 1219-1227.
2. J.E. Allison, L.C. Sakoda, T.R. Levin, J.P. Tucker, I.S. Tekawa, T. Cuff, M.P. Pauly, L. Shlager, A.M. Palitz, W.K. Zhao, J.S. Schwartz, D.F. Ransohoff and J.V. Selby, Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics, J. Natl. Cancer Inst. 99 (2007), 1462-1470.
3. D.E. Brenner and G. Rennert, Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible?, J. Natl. Cancer Inst. 97 (2005), 1107-1109.
4. D. Calistri, C. Rengucci, R. Bocchini, L. Saragoni, W. Zoli and D. Amadori, Fecal multiple molecular tests to detect colorectal cancer in stool, Clin. Gastroenterol. Hepatol. 1 (2003), 377-383.
5. D. Calistri, C. Rengucci, A. Lattuneddu, G. Francioni, A.M. Polifemo, O. Nanni, L. Saragoni, F. Monti, A. Ravaioli, W. Zoli and D. Amadori, Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool, Neoplasia 6 (2004), 536-540.
6. R.J. Davies, R. Miller and N. Coleman, Colorectal cancer screening: prospects for molecular stool analysis, Nat. Rev. Cancer 5 (2005), 199-209.
7. J.A. Fisher, C. Fikry and A.B. Troxel, Cutting cost and increasing access to colorectal cancer screening: another approach to following the guidelines, Cancer Epidemiol. Biomarkers Prev. 15 (2006), 108-113.
8. E. Flamini, L. Mercatali, O. Nanni, D. Calistri, R. Nunziatini, W. Zoli, P. Rosetti, N. Gardini, A. Lattuneddu, G.M. Verdecchia and D. Amadori, Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer, Clin. Cancer Res. 12 (2006), 6985-6988.
9. C.G. Fraser, C.M. Mathew, N.A. Mowat, J.A. Wilson, F.A. Carey and R.J. Steele, Evaluation of a card collection-based faecal immunochemical test in screening for colorectal cancer using a two-tier reflex approach, Gut 56 (2007), 1415-1418.
10. From the Centers for Disease Control and Prevention. Colorectal cancer test use among persons aged ≥50 years - United States, 2001, JAMA 289 (2003), 2492-2493.
11. K. Garber, New gene discoveries may boost DNA stool testing for colorectal cancer, J. Natl. Cancer Inst. 96 (2004), 820-821.
12. U. Haug and H. Brenner, A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy, Cancer Epidemiol. Biomarkers Prev. 14 (2005), 422-428.
13. U. Haug, M.N. Wente, C.M. Seiler, D. Rothenbacher, M.W. Buchler and H. Brenner, Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting, Clin. Chem. 52 (2006), 782-784.
14. T.F. Imperiale, D.F. Ransohoff, S.H. Itzkowitz, B.A. Turnbull and M.E. Ross, Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population, N. Engl. J. Med. 351 (2004), 2704-2714.
15. S.H. Itzkowitz, L. Jandorf, R. Brand, L. Rabeneck, P.C. Schroy 3rd, S. Sontag, D. Johnson, J. Skoletsky, K. Durkee, S. Markowitz and A. Shuber, Improved fecal DNA test for colorectal cancer screening, Clin. Gastroenterol. Hepatol. 5 (2007), 111-117.
16. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, A. Ghafoor, E.J. Feuer and M.J. Thun, Cancer statistics, 2005, CA Cancer J. Clin. 55 (2005), 10-30.
17. Z. Levi, P. Rozen, R. Hazazi, A. Vilkin, A. Waked, E. Maoz, S. Birkenfeld, M. Leshno and Y. Niv, A quantitative immunochemical fecal occult blood test for colorectal neoplasia, Ann. Intern. Med. 146 (2007), 244-255.
18. A. Loktionov, I.K. O'Neill, K.R. Silvester, J.H. Cummings, S.J. Middleton and R. Miller, Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer, Clin. Cancer Res. 4 (1998), 337-342.
19. H.M. Muller, M. Oberwalder, H. Fiegl, M. Morandell, G. Goebel, M. Zitt, M. Muhlthaler, D. Ofner, R. Margreiter and M. Widschwendter, Methylation changes in faecal DNA: a marker for colorectal cancer screening?, Lancet 363 (2004), 1283-1285.
20. N.K. Osborn and D.A. Ahlquist, Stool screening for colorectal cancer: molecular approaches, Gastroenterology 128 (2005), 192-206.
21. C. Rengucci, P. Maiolo, L. Saragoni, W. Zoli, D. Amadori and D. Calistri, Multiple detection of genetic alterations in tumors and stool, Clin. Cancer Res. 7 (2001), 590-593.
22. D. Sidransky, T. Tokino, S.R. Hamilton, K.W. Kinzler, B. Levin, P. Frost and B. Vogelstein, Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors, Science 256 (1992), 102-105.
23. K. Song, A.M. Fendrick and U. Ladabaum, Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis, Gastroenterology 126 (2004), 1270-1279.
24. G. Traverso, A. Shuber, B. Levin, C. Johnson, L. Olsson, D.J. Schoetz Jr., S.R. Hamilton, K. Boynton, K.W. Kinzler and B. Vogelstein, Detection of APC mutations in fecal DNA from patients with colorectal tumors, N. Engl. J. Med. 346 (2002), 311-320.
25. G. Traverso, A. Shuber, L. Olsson, B. Levin, C. Johnson, S.R. Hamilton, K. Boynton, K.W. Kinzler and B. Vogelstein, Detection of proximal colorectal cancers through analysis of faecal DNA, Lancet 359 (2002), 403-404.
26. N. Umetani, J. Kim, S. Hiramatsu, H.A. Reber, O.J. Hines, A.J. Bilchik and D.S. Hoon, Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats, Clin. Chem. 52 (2006), 1062-1069.
27. S. Vijan, E.W. Hwang, T.P. Hofer and R.A. Hayward, Which colon cancer screening test? A comparison of costs, effectiveness, and compliance, Am. J. Med. 111 (2001), 593-601.
28. H. Zou, J.J. Harrington, K.K. Klatt and D.A. Ahlquist, A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening, Cancer Epidemiol. Biomarkers Prev. 15 (2006), 1115-1119.